Medical Scientist Training Program, Miller School of Medicine, University of Miami, Miami, FL 33136, USA.
Department of Microbiology and Immunology, Miller School of Medicine, University of Miami, Miami, FL 33136, USA.
Int J Mol Sci. 2022 Jan 20;23(3):1097. doi: 10.3390/ijms23031097.
Sepsis has recently been defined as life-threatening organ dysfunction caused by the dysregulated host response to an ongoing or suspected infection. To date, sepsis continues to be a leading cause of morbidity and mortality amongst hospitalized patients. Many risk factors contribute to development of sepsis, including pain-relieving drugs like opioids, which are frequently prescribed post-operatively. In light of the opioid crisis, understanding the interactions between opioid use and the development of sepsis has become extremely relevant, as opioid use is associated with increased risk of infection. Given that the intestinal tract is a major site of origin of sepsis-causing microbes, there has been an increasing focus on how alterations in the gut microbiome may predispose towards sepsis and mediate immune dysregulation. MicroRNAs, in particular, have emerged as key modulators of the inflammatory response during sepsis by tempering the immune response, thereby mediating the interaction between host and microbiome. In this review, we elucidate contributing roles of microRNA 146 in modulating sepsis pathogenesis and end with a discussion of therapeutic targeting of the gut microbiome in controlling immune dysregulation in sepsis.
脓毒症最近被定义为危及生命的器官功能障碍,是由宿主对持续或疑似感染的失调反应引起的。迄今为止,脓毒症仍然是住院患者发病率和死亡率的主要原因。许多危险因素导致脓毒症的发生,包括术后经常开的止痛药,如阿片类药物。鉴于阿片类药物危机,了解阿片类药物使用与脓毒症发展之间的相互作用变得非常重要,因为阿片类药物的使用与感染风险增加有关。鉴于肠道是导致脓毒症的微生物的主要起源部位,人们越来越关注肠道微生物组的改变如何导致脓毒症,并调节免疫失调。特别是 microRNA,已成为脓毒症炎症反应的关键调节剂,通过调节免疫反应,从而调节宿主与微生物组之间的相互作用。在这篇综述中,我们阐明了 microRNA 146 在调节脓毒症发病机制中的作用,并以讨论靶向肠道微生物组治疗脓毒症免疫失调结束。